Tag: Syncona

Achilles’ US IPO closed with proceeds of $175m

by Selina McKee | Apr 8, 2021 | News | 0

The Cancer Research UK spinout is developing precision T cell therapies to treat multiple cancers

Gyroscope Theraputics secures £50.4m Series B financing

by Anna Smith | Sep 3, 2019 | News | 0

Syncona and Cambridge Innovation Capital will contribute £48 million and £2.4 million, respectively.

Syncona’s Nightstar Therapeutics to be bought by Biogen for $877 million

by Anna Smith | Mar 4, 2019 | News | 0

Nightstar Therapeutics has agreed to be acquired by Biogen.

Plans unveiled for new life sciences investment group

by Selina McKee | Nov 7, 2016 | News | 0

Cancer Research UK is linking with the Wellcome Trust and investment groups Syncona and BACIT to create a new company, to be listed on the London Stock Exchange with assets of up to £1 billion, that will stream funds into life sciences.

Syncona, CRT create new company Achilles

by Selina McKee | Oct 5, 2016 | News | 0

Syncona and Cancer Research Technology have announced the launch of a new private company – Achilles Therapeutics – that will bring together research from University College London and the Francis Crick Institute, funded by Cancer Research UK and the National Institute for Health Research.